Next Science Limited

Next Science Limited is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. It is listed on the ASX under ASX Code ‘NXS’. Next Science’s primary focus is the development and continued commercialisation of its proprietary Xbio^TM technology to reduce the impact of biofilm based infections in human health.

Traditionally, researchers attempting to eradicate difficult-to-treat bacteria have based their efforts on better understanding the bacteria themselves. These efforts have been largely unsuccessful.

Next Science approaches this problem from a different perspective. By applying the principles of material science to a material science problem, Next Science researchers first noticed that the structure of bacterial biofilms behave in ways very similar to those of rubber: both have cross-linked polymers that swell and break apart when fuels pass through them. The Next Science team then devised methods for dissolving these protective bacterial polymers and thus exposing the bacteria to subsequent attack, creating a revolutionary breakthrough for modern science.